In the case of the simultaneous action of chrysin as a BCRP/ABCG2 inhibitor, an increase in the toxicity of the cytostatic drug sorafenib was observed in the HCC cell line (Hep3B and HepG2) [215]. The gene discussed is ABCG2; the disease is hepatocellular carcinoma.